Linking the Plasma Proteome to Echocardiographic Parameters in Patients with Chronic Heart Failure
Explore the role of high-plex proteomics in providing deeper insights into heart failure pathophysiology
Recent advancements in proteomic profiling have unlocked new possibilities for understanding the complex mechanisms that drive heart failure
Measuring thousands of proteins simultaneously makes it possible to capture a comprehensive overview of the patient’s health state and investigate underlying disease progression at a subclinical level.
Webinar highlights:
- How the SomaScan™ Assay was used to measure 4,210 plasma proteins in 173 patients with heart failure over a median follow-up of 2.7 years, revealing significant associations with echocardiographic parameters
- How to understand the diverse pathways involved in cardiac disfunction by performing distinct associations between specific proteins and echocardiographic parameters
- How these proteomic insights can inform the development of targeted therapies and improve risk stratification in chronic heart failure patients
Isabella Kardys, MD, PhD
Erasmus University Medical Center
Isabella Kardys is a professor of translational cardiovascular epidemiology at Erasmus University Medical Center where she leads a research line focused on innovative methodological approaches in clinical epidemiological studies of acquired heart disease, particularly emphasizing serially measured blood biomarkers.
Linking the Plasma Proteome to Echocardiographic Parameters in Patients with Chronic Heart Failure
A presentation by Isabella Kardys, MD, PhD
More webinars
WebinarPathways to Digital Health: AI and Omics in Rheumatoid Arthritis
Explore how groundbreaking proteomic research is transforming our understanding of rheumatoid arthritis (RA). In this on-demand webinar, Allan Stensballe, PhD, shares new insights into the molecular landscape of RA-affected synovial tissue, revealing how autoantibodies and protein signatures may hold the key to more precise personalized therapies.
WebinarUsing Antibody Profiling to Identify Novel Diagnostic Biomarkers
Current cancer screening methods often lead to false positives, false negatives and invasive biopsies that lack prognostic insights. Emerging research suggests that cancer-specific IgM and IgG antibodies – produced by B cells upon recognizing malignant cells – could serve as stable, easily measurable blood biomarkers for detecting and monitoring high-incidence cancers like melanoma and breast, prostate, bowel, lung and pancreatic cancer. This approach has the potential to improve early diagnosis, reduce uncertainty and enhance treatment planning.
WebinarB Cell Repertoire in Determining Responses to Checkpoint Blockade in NSCLC
In this webinar, Gary Middleton, MD, PhD, and Akshay Patel, PhD, from the University of Birmingham explore the role of the B cell repertoire and autoantibodies in shaping responses to checkpoint blockade immunotherapy in non-small-cell lung cancer (NSCLC). They demonstrate how autoantibody profiling using the i-Ome™ Discovery protein microarray revealed biomarkers predictive of treatment efficacy and immune-related adverse events (irAEs), providing insights into biomarker development and personalized immunotherapy strategies.